Forte Biosciences, Inc.
FBRX
$12.65
-$1.01-7.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.18% | 45.04% | 56.92% | 103.24% | 40.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.36% | 12.67% | 14.78% | 53.47% | 83.34% |
| Operating Income | -34.36% | -12.67% | -14.78% | -53.47% | -83.34% |
| Income Before Tax | -36.00% | -12.71% | -12.18% | -49.45% | -77.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.00% | -12.71% | -12.18% | -49.45% | -77.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.00% | -12.71% | -12.18% | -49.45% | -77.93% |
| EBIT | -34.36% | -12.67% | -14.78% | -53.47% | -83.34% |
| EBITDA | -84.04% | -120.39% | -135.04% | -345.75% | -114.75% |
| EPS Basic | 43.05% | 41.76% | 40.18% | 28.84% | -3.76% |
| Normalized Basic EPS | 43.05% | 41.76% | 40.18% | 28.84% | -3.76% |
| EPS Diluted | 43.05% | 41.76% | 40.18% | 28.84% | -3.76% |
| Normalized Diluted EPS | 43.05% | 41.76% | 40.18% | 28.84% | -3.76% |
| Average Basic Shares Outstanding | 250.90% | 131.24% | 82.83% | 114.89% | 99.60% |
| Average Diluted Shares Outstanding | 250.90% | 131.24% | 82.83% | 114.89% | 99.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |